Outcomes of patients with indolent lymphoma treated with bendamustine plus rituximab compared to rituximab plus CVP or CHOP chemoimmunotherapy in Ontario
British Journal of Haematology · 2023
DOI: 10.1111/bjh.18972 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2023. Verfasst von Adam Suleman und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Lymphoma, Non-Hodgkin. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: American Society of Hematology.
Abstract (Originalsprache)
Bendamustine (B) with rituximab (R) has become the preferred regimen for patients with indolent lymphoma in Ontario, Canada, compared to R with cyclophosphamide, vincristine, prednisone (CVP) or cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP). We conducted a propensity‐matched retrospective cohort population‐based study of patients treated with R‐CVP/CHOP from 2005 to 2012 and patients treated with BR from 2013 to 2018. The primary outcome was 5‐year overall survival (OS), and secondary outcomes included toxicities and healthcare utilization. The 5‐year OS for patients treated with BR ( n = 2023) and R‐CVP/CHOP ( n = 2023) was 80% and 75% respectively. Treatment with BR was associated with improved OS (HR 0.79, 95% CI 0.69–0.91). During the first 9 months, patients treated with BR versus R‐CVP/CHOP had a higher number of admissions for infection (22% compared to 17%, p < 0.01) and a higher number of mean ED visits (mean 1.01 ± 1.68 visits vs. 0.85 ± 1.51 visits, p < 0.01). This trend persisted for 3 years. The adjusted 5‐year OS for patients 75 years and older did not differ based on treatment regimen (55.5% for BR vs. 55.4% for R‐CVP/CHOP). Our study supports the use of BR for patients with indolent lymphoma requiring treatment but suggests increased risk of certain toxicities warranting careful patient selection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
- Institute for Clinical Evaluative Sciences (ICES), Toronto, Ontario, Canada.
- Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
- Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
ORCID-Profile: Adam Suleman, Kelvin K W Chan, Matthew C Cheung, Anca Prica
Förderung
- American Society of Hematology
Zitieren
APA
Suleman, A., Aktar, S. J., Ante, Z., Liu, N., Chan, K. K. W., Cheung, M. C., & Prica, A. (2023). Outcomes of patients with indolent lymphoma treated with bendamustine plus rituximab compared to rituximab plus CVP or CHOP chemoimmunotherapy in Ontario. British Journal of Haematology. https://doi.org/10.1111/bjh.18972
Vancouver
Suleman A, Aktar SJ, Ante Z, Liu N, Chan KKW, Cheung MC, et al. Outcomes of patients with indolent lymphoma treated with bendamustine plus rituximab compared to rituximab plus CVP or CHOP chemoimmunotherapy in Ontario. British Journal of Haematology. 2023. doi:10.1111/bjh.18972
BibTeX
@article{Suleman2023,
author = {Suleman, Adam and Aktar, Suriya J and Ante, Zharmaine and Liu, Ning and Chan, Kelvin K W and Cheung, Matthew C and Prica, Anca},
title = {Outcomes of patients with indolent lymphoma treated with bendamustine plus rituximab compared to rituximab plus CVP or CHOP chemoimmunotherapy in Ontario},
journal = {British Journal of Haematology},
year = {2023},
doi = {10.1111/bjh.18972}
}
EUVIMED